PADDINGTON

Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196

 Coordinatore SIENA BIOTECH SPA 

 Organization address address: Via Banchi di Sotto 34
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Enrica
Cognome: Diodato
Email: send email
Telefono: +39 0577 381454
Fax: +39 0577 381208

 Nazionalità Coordinatore Italy [IT]
 Sito del progetto http://www.paddingtonproject.eu
 Totale costo 8˙589˙885 €
 EC contributo 5˙816˙313 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-single-stage
 Funding Scheme CP-FP
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-07-01   -   2013-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    SIENA BIOTECH SPA

 Organization address address: Via Banchi di Sotto 34
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Enrica
Cognome: Diodato
Email: send email
Telefono: +39 0577 381454
Fax: +39 0577 381208

IT (SIENA) coordinator 1˙540˙673.80
2    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 20 3108 3033
Fax: +44 20 7813 2849

UK (LONDON) participant 2˙001˙045.20
3    UNIVERSITAET ULM

 Organization address address: HELMHOLTZSTRASSE 16
city: ULM
postcode: 89081

contact info
Titolo: Mr.
Nome: Frank
Cognome: Gleixner
Email: send email
Telefono: +49 731 500 66397
Fax: +49 731 500 66392

DE (ULM) participant 1˙104˙681.20
4    KCR SA

 Organization address address: UL. POSTEPU 6
city: WARSZAWA
postcode: 02 676

contact info
Titolo: Dr.
Nome: Agnieszka
Cognome: Felicja?czuk
Email: send email
Telefono: +48 22 31 3 13 31
Fax: +48 22 313 13 14

PL (WARSZAWA) participant 916˙669.90
5    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

 Organization address address: KEPPEL STREET
city: LONDON
postcode: WC1E7HT

contact info
Titolo: Ms.
Nome: Dawn
Cognome: Carpenter
Email: send email
Telefono: 442079000000
Fax: 442076000000

UK (LONDON) participant 253˙243.60

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

progression    huntington    sen    compound    clinical    disease   

 Obiettivo del progetto (Objective)

'The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the EU as of September 2, 2009. A multi-factorial approach will be used, including assessment of both novel and compound-specific measures of molecular action as well as previously identified predictors of disease progression. The translational approaches addressed by this project are instrumental in the progression of SEN0014196 to clinical proof-of-concept and, if successful, will play a pivotal role in patient stratification and outcomes research. The Consortium will comprise four partners, all with a proven track-record in Research and Development in the Huntington’s Disease area. All Partners are based within the EU.'

Introduzione (Teaser)

Huntington's disease (HD) is a devastating progressive disorder. Delaying disease onset requires novel targeted interventions early on in life.

Altri progetti dello stesso programma (FP7-HEALTH)

BALANCE (2012)

Development of a bioartificial liver therapy in acute liver failure

Read More  

BRIDGE (2009)

Scoping study of approaches to Brokering knowledge and Research Information to support the Development and Governance of health systems in Europe

Read More  

SDH-NET (2011)

Building Sustainable Research capacity for Health and its Social Determinants in Low- and Middle-Income Countries

Read More